PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron…
Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING…
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of…